The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in children for the first time, it said on Saturday.
The new mid-stage trial will determine whether the vaccine is effective on people between the ages of 6 and 17, according to an emailed statement from the university.
Around 300 volunteers will be enrolled and first inoculations are expected this month, Oxford said.
The two-dose Oxford/AstraZeneca vaccine has been hailed as a "vaccine for the world" because it is cheaper and easier to distribute than some rivals.
AstraZeneca has a target to produce 3 billion doses this year and aims to produce over 200 million doses per month by April.
Putin says US-Russia contacts beneficial as talks begin with Witkoff and Kushner
Chinese national rescued from Nepal tunnel 10 days after flash flood
US envoys Witkoff, Kushner arrive in Moscow for talks on peace in Ukraine
One dead, 11 people missing after mudslide in China's Jiangxi province
Philippine VP Duterte posts bail after arrest order for alleged grave threats
Lindsay Clancy trial over killing her children ends in mistrial
Israel says it strikes southern Lebanon after Hezbollah drone launch
Sydney sweats in spring hot spell, faces 'extreme' bushfire risk
